AKBA
Akebia Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Akebia Therapeutics has 8 disclosed suppliers and 13 disclosed customers in SEC filings.
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−26.02%
vs ±35.9% implied · ×0.73
shaded = implied · ▲▼ = realized
Akebia Therapeutics, Inc.
0.71
SentenceOn November 28, 2025, we entered into an Asset Purchase Agreement with Akebia Therapeutics, Inc. ("Akebia") pursuant to which we sold to Akebia substantially all of our assets related to the research, development, manufacture and commercialization of ADX-097 (the "ADX-097 Asset Sale").
SentenceThe Panion Amended License Agreement provides us with an exclusive license under Panion-owned know-how and patents covering the rights to sublicense, develop, make, use, sell, offer for sale, import and export ferric citrate worldwide, excluding certain Asian Pacific countries, or the Licensor Territory .
AKBA 10-Kaccession 0001517022-26-000020
SentenceWe have entered into supply agreements with STA Pharmaceutical Hong Kong Limited, or STA , for the manufacture of Vafseo drug substance and drug product for commercial use and Patheon Inc. for the manufacture of Vafseo drug product for commercial use.
AKBA 10-Kaccession 0001517022-26-000020
SentenceA uryxia drug product is supplied by Patheon Manufacturing Services LLC (Thermo Fisher) pursuant to a Master Manufacturing Service Agreement with per-bottle pricing structured on a tiered basis, with the price reduced as the product volume increases.
AKBA 10-Kaccession 0001517022-26-000020
SentenceOn November 28, 2025, or the APA Closing Date , we entered into an Asset Purchase Agreement, or the Q32 Purchase Agreement , with Q32, pursuant to which we purchased and assumed from Q32 substantially all assets and liabilities of Q32 and its affiliates related to the research, development, manufacture and commercialization of Q32's clinical-stage development candidate known as ADX-097, now referred to as AKB-097, worldwide for the treatment, prevention or diagnosis of any disease or condition in humans.
AKBA 10-Kaccession 0001517022-26-000020
SentenceWe have entered into supply agreements with STA Pharmaceutical Hong Kong Limited, or STA , for the manufacture of Vafseo drug substance and drug product for commercial use and Patheon Inc. for the manufacture of Vafseo drug product for commercial use.
AKBA 10-Kaccession 0001517022-26-000020
On December 22, 2022, we and Averoa entered into a license agreement, or Averoa License Agreement , pursuant to which we granted to Averoa an exclusive license to develop and commercialize ferric citrate, or Averoa Licensed Product, in the EEA, Turkey, Switzerland and the United Kingdom, and in August 2024, we also granted Averoa an exclusive license to develop and commercialize ferric citrate in the Balkans and certain countries in Eastern Europe and the Middle East, or collectively, the Averoa Territory .
AKBA 10-Kaccession 0001517022-26-000020
SentenceOn February 18, 2022, we entered into a Second Amended and Restated License Agreement, or the Vifor License Agreement , with Vifor (International) Ltd. (now a part of CSL Limited), or CSL Vifor , which amended and restated the License Agreement dated as of May 12, 2017.
AKBA 10-Kaccession 0001517022-26-000020
SentenceTogether with Dialysis Clinic, Inc. or DCI , and Innovative Renal Care, or IRC , these top five U.S. dialysis organizations treat 82% of the total dialysis patient population.
AKBA 10-Kaccession 0001517022-26-000020
SentenceMost dialysis clinics operate within dialysis organization networks, the largest of which are DaVita, Inc., or DaVita , Fresenius KidneyCare Group LLC, or Fresenius , and U.S. Renal Care, or USRC .
AKBA 10-Kaccession 0001517022-26-000020
SentenceIn February 2021, we entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or HCR , whereby we sold our right to receive royalties and sales milestones for Vafseo in Japan and certain other Asian countries in the TPC territory under the TPC Agreement, subject to certain caps and other terms and conditions.
AKBA 10-Kaccession 0001517022-26-000020
SentenceTogether with Dialysis Clinic, Inc. or DCI , and Innovative Renal Care, or IRC , these top five U.S. dialysis organizations treat 82% of the total dialysis patient population.
AKBA 10-Kaccession 0001517022-26-000020
SentenceIn September 2007, we entered into a Sublicense Agreement with JT and Torii, under which JT and Torii obtained the exclusive sublicense rights for the development and commercialization of ferric citrate in Japan.
AKBA 10-Kaccession 0001517022-26-000020
SentenceOn May 24, 2023, or the Medice Effective Date , we entered into a License Agreement, or the Medice License Agreement , with Medice, under which we granted to Medice an exclusive license to develop and commercialize Vafseo for the treatment of anemia in adult patients with chronic kidney disease in the European Economic Area, or EEA , UK, Switzerland and Australia, or the Medice Territory .
AKBA 10-Kaccession 0001517022-26-000020
SentenceOn February 5, 2025, we entered into an Authorized Generic Distribution and Supply Agreement with Mylan Pharmaceuticals, Inc., as amended in September 2025, pursuant to which, they are currently selling an authorized generic version of Auryxia.
AKBA 10-Kaccession 0001517022-26-000020
SentenceIn December 2015, we entered into a collaboration agreement with Tanabe Pharma Corporation, or TPC , formerly known as Mitsubishi Tanabe Pharma Corporation, as amended, or the TPC Agreement , providing TPC with exclusive development and commercialization rights to Vafseo in Japan and certain other Asian countries, or the TPC Territory .
AKBA 10-Kaccession 0001517022-26-000020
SentenceIn September 2007, we entered into a Sublicense Agreement with JT and Torii, under which JT and Torii obtained the exclusive sublicense rights for the development and commercialization of ferric citrate in Japan.
AKBA 10-Kaccession 0001517022-26-000020
SentenceMost dialysis clinics operate within dialysis organization networks, the largest of which are DaVita, Inc., or DaVita , Fresenius KidneyCare Group LLC, or Fresenius , and U.S. Renal Care, or USRC .
AKBA 10-Kaccession 0001517022-26-000020
Linked news
Expected move
No implied move.